The plasma Grifols Group collects in Canada will support the company's long-term collaboration agreement with Canadian Blood Services, announced in September 2022, to increase Canada's self-sufficiency in immunoglobulin (Ig) medicines through an all-Canadian supply chain. Grifols Group is working with Canadian Blood Services to steadily increase sourcing of the Canadian plasma necessary so that volumes eventually reach the agreed-to 600,000 liters to manufacture 2.4 million grams of Ig treatments annually by 2026. Production is exclusively for Canadian Blood Services and Canadian patients.